SASKATOON, Saskatchewan, Nov. 28, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a growing national platform for pharmacist-led community pharmacy ownership, today reported its financial results for the three and nine months ended September 30, 2025.
The third quarter reflected continued operational momentum, increased financial performance from individual pharmacy locations, driven by higher revenues, improved margins, better operating efficiencies, and disciplined progress on the Corporation’s national acquisition strategy. Following quarter-end, PharmaCorp completed the acquisitions of 3 pharmacies, 2 located in Western Canada and 1 located in Eastern Canada, building further scale and reinforcing the platform’s coast-to-coast ambitions.
Q3 2025 Financial Highlights
- Revenues are driven by continuous increases in prescription volumes and front-of-store sales
- Same-store sales, a supplementary financial measure, increased 9.4% year-over-year compared to Q3 2024, reflecting continued organic growth across our pharmacy network
- Prescription volumes continue to grow, with total script count rising 7.2% year-over-year compared to Q3 2024, demonstrating sustained patient engagement and activity across the network
- Operating infrastructure was successfully deployed to support national scalability, including systems integration, pharmacy onboarding, and co-ownership execution
- Net loss for the quarter reflects continued investment in corporate infrastructure, stock options granted to directors and officers on July 18, 2025, as well as one-time legal fees to obtain our credit facility with CIBC
- Solid pharmacy-level contribution margins and a disciplined weighted average EBITDA multiples across acquisitions support PharmaCorp’s long-term accretive growth model
Management Commentary
“We’re encouraged by the strong performance of our initial acquisitions and by the ongoing interest from independent pharmacy owners considering their succession options,” said Alan Simpson, Executive Chairman of PharmaCorp. “This quarter demonstrates steady progress in scaling the business through disciplined, methodical execution. We remain committed to maintaining a disciplined weighted average EBITDA multiple across transactions, reinforcing our objective of achieving accretive growth.”
Operational Update
During the quarter, the Corporation made key investments in systems, personnel, and integration processes necessary to support scalable national growth. The reported net loss includes options which were granted to directors and officers on July 18, 2025, and one-time legal fees to obtain our credit facility with CIBC.
Subsequent Events
On October 2, 2025, PharmaCorp announced that it purchased a 100% interest in two pharmacies located in Western Canada, one of which includes the associated land and building. The aggregate purchase price for the 100% interest was $3,400,000 and was funded from cash and shares.
On October 2, 2025, PharmaCorp announced that it purchased a 100% interest in a pharmacy located in Eastern Canada. The aggregate purchase price for the 100% interest was $5,300,000 and was funded from cash and available funds under the Corporation’s credit facility.
On November 12, 2025, PharmaCorp announced that it closed its previously announced bought deal public offering co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Limited, and including Raymond James Ltd., iA Private Wealth Inc., and Bloom Burton Securities Inc. (the “Underwriters”) pursuant to which the Underwriters purchased, on a bought deal basis, 54,855,000 units (the “Units”) in the capital of the Corporation at a price of C$0.42 per Unit for aggregate gross proceeds to PharmaCorp of approximately C$23.0 million, which included the full exercise of the over-allotment option.
Further Information
For comprehensive disclosure of PharmaCorp’s financial performance for the three and nine months ended September 30, 2025 and its financial position as at such date, please see PharmaCorp’s unaudited Condensed Consolidated Interim Financial Statements and related Management’s Discussion and Analysis for the three and nine months ended September 30, 2025 filed on SEDAR+ at www.sedarplus.ca.
Supplementary Financial Measures
This news release also makes reference to “same-store sales”, which is a supplementary financial measure. “Same-store sales” is defined as sales from pharmacy locations owned and operated by PharmaCorp as at the current reporting period end and historical sales information from the pharmacies operating systems. It is used to provide investors with a supplemental measure of the Corporation’s operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management uses supplementary financial measures such as same-store sales in order to facilitate operating performance comparisons from period to period. Management also believes that supplementary financial measures are meaningful to investors because they enable investors to better understand the level of growth of our business. The Corporation cautions readers that same-store sales used in this news release may not be comparable to similar measures used by other issuers.
About PharmaCorp Rx Inc.
PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. Through a combination of capital, strategic support, and operational expertise, PharmaCorp is building a national network of community pharmacies under the PharmaChoice Canada banner. PharmaCorp currently operates seven PharmaChoice Canada bannered pharmacies and will continue to acquire both PharmaChoice Canada bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform in accordance with its strategic alliance with PharmaChoice Canada. PharmaCorp shares trade on the TSX Venture Exchange under the symbol: PCRX.
PharmaCorp actively welcomes discussions with pharmacy owners considering succession or sale. For more information about our acquisition program and process, please visit www.PharmaCorpRx.ca or contact our team confidentially. We are committed to seamless transitions that protect your legacy and serve your community.
For further information, please contact:
Investor Relations
info@pharmacorprx.ca
Tel: (306) 536-3771
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains “forward-looking information” regarding the Corporation within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the Corporation’s disciplined progress on the Corporation’s national acquisition strategy; the Corporation’s coast-to-coast platform and acquisitions ambitions; the Corporation’s long-term accretive growth model; the ongoing interest from independent pharmacy owners considering succession options; the Corporation’s commitment to maintaining a disciplined weighted average EBITDA multiple across transactions, reinforcing the Corporation’s objective of achieving accretive growth; and the Corporation’s goal to continue to acquire pharmacies as they come to market and to operate such pharmacies under the PharmaChoice Canada banner. This forward-looking information reflects current beliefs and is based on information currently available to the management of the Corporation and on assumptions the Corporation believes are reasonable. These assumptions include, but are not limited to: the ongoing interest from independent pharmacy owners considering succession options; the volume of acquisition opportunities presented to the Corporation being equal to or greater than historical volumes; and the continued supply of pharmacies for purchase by the Corporation at prices satisfactory to the Corporation and the ability of the Corporation to acquire such pharmacies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board of directors, third party or regulatory approvals; competition; changes in legislation, including pharmacy regulation, affecting the Corporation; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; and lack of qualified, skilled labour or loss of key individuals. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Corporation’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of the Corporation as of the date of this news release and, accordingly, is subject to change after such date. However, the Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
